TCTR20151209001Enrolling By Invitation未知
Effectiveness of 14-day standard triple therapy with four timesâ€daily dosing of amoxicillin and sequential therapy for Helicobacter pylori eradication in Thai patients with functional dyspepsia
The human ethics committee of thammasat university0 个研究点目标入组 100 人开始时间: 2015年12月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •who underwent gastroscopic examination at Thammasat University
- •Hospital, for dyspeptic symptoms between Februry 2015
- •and Februry 2016 were enrolled. After the endoscopy,
- •those with diagnosis of non-ulcer dyspepsia, which was
- •established during gastroscopy with normal finding or
- •mild gastritis, were considered for entry in this study.
排除标准
- •- patients with a history of prior H. pylori eradication
- •- previous gastric surgery
- •- pregnancy, lactation, major systemic diseases, cardiovascular disease
- •- administration of antibiotics and PPI drugs in the preceding 4 weeks
- •- allergy to any one of the given medication in the regimens
研究者
相似试验
招募中
4 期
A clinical trial to compare the efficacy of 7-day and 14-day triple drug therapy for the eradication treatment of Helicobacter pylori infectioCTRI/2011/11/002139Pradeep Kumar P320
已完成
不适用
Comparison of standard vs. concomitant eradication therapyKCT0000613Kyungpook National University Medical Center348
尚未招募
不适用
Efficacy of 1 week and 2 weeks standard triple therapy for the eradication of clarithromycin-sensitive helicobacter pylori infectioDiseases of the digestive systemKCT0005309Inje University Haeundae Paik Hospital180
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FRovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-NLovo Nordisk A/S288